Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 5Seizures 4Marijuana Abuse 3Colonic Neoplasms 3Breast Neoplasms 3Sturge-Weber Syndrome 2Nausea 2Lennox Gastaut Syndrome 2Glioblastoma 2Epilepsies, Myoclonic 2Anxiety Disorders 2Vomiting 1Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Parasomnias 1Pancreatic Neoplasms 1Pain 1Neoplasms 1Multiple Myeloma 1Liver Neoplasms 1Liver Cirrhosis 1Gallbladder Neoplasms 1Epilepsy 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1

Interventions

Exercise 6Transcranial Direct Current Stimulation 4Walking 3Memantine 3Tablets 2Standard of Care 2Methods 2Donepezil 2Cognitive Behavioral Therapy 2mazdutide 1lithium sulfate 1lime 1fasudil 1enzalutamide 1blueberry extract 1beta Carotene 1acetaminophen, aspirin, caffeine drug combination 1XENP 1595 1Vitamin E 1Vitamin D 1Ultraviolet Therapy 1Transcranial Magnetic Stimulation 1Time 1Therapeutics 1Tai Ji 1Sugars 1Sodium Chloride 1Sirolimus 1Silymarin 1Riluzole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cognitive Dysfunction × Cannabidiol × Clear all
NCT04447846 2023-05-25

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
11 enrolled 25 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡